The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points to a new indication approval for Pfizer (NYSE: PFE)’s JAK1 inhibitor Cibinqo (abrocitinib), a small molecule targeted therapy. This approval expands the drug’s use to include the treatment of moderate to severe atopic dermatitis (AD) in adolescents and adults aged 12 and above.
Cibinqo was initially approved in China to treat adult patients with moderate to severe AD in April 2022, and it was included in the National Reimbursement Drug List (NRDL) in 2023. The regulatory JADETEEN study, which analyzed the drug’s efficacy and safety in a Chinese subgroup of adolescent AD patients, demonstrated positive results. Additionally, Cibinqo has been registered in the UK, Japan, and the US, among other countries, for the treatment of adolescents aged 12 years and older, as well as adults with moderate to severe AD.- Flcube.com
